Stock 4572 CARNA BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Carna Biosciences, Inc.

Equities

4572

JP3220550002

Biotechnology & Medical Research

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-05-02 am EDT 		5-day change 1st Jan Change
408 JPY -3.32% Intraday chart for Carna Biosciences, Inc. -10.72% -21.84%
Mar. 07 Fresh Tracks Therapeutics, Inc. and Carna Biosciences, Inc. Enters into Termination of License Agreement CI
2023 Carna Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 9,122 24,246 15,031 14,666 7,390 8,950
Enterprise Value (EV) 1 8,452 20,058 11,160 11,388 4,310 6,243
P/E ratio -7.2 x 28.5 x -13.4 x -26.2 x -5.25 x -7.61 x
Yield - - - - - -
Capitalization / Revenue 12.1 x 7.56 x 13.3 x 7.27 x 5.33 x 5.51 x
EV / Revenue 11.2 x 6.25 x 9.85 x 5.65 x 3.11 x 3.84 x
EV / EBITDA -7.46 x 20.3 x -10.7 x -22.2 x -3.48 x -5.77 x
EV / FCF -10.6 x 17.9 x -11.3 x -7.85 x -11.8 x -4.84 x
FCF Yield -9.45% 5.58% -8.87% -12.7% -8.46% -20.7%
Price to Book 10.3 x 6.42 x 3.93 x 3.4 x 2.03 x 2.31 x
Nbr of stocks (in thousands) 10,136 11,421 12,402 13,308 14,211 17,145
Reference price 2 900.0 2,123 1,212 1,102 520.0 522.0
Announcement Date 3/27/19 3/27/20 3/26/21 3/25/22 3/27/23 3/27/24
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 754 3,207 1,133 2,017 1,386 1,625
EBITDA 1 -1,133 987 -1,045 -512 -1,237 -1,082
EBIT 1 -1,145 978 -1,057 -531 -1,270 -1,117
Operating Margin -151.86% 30.5% -93.29% -26.33% -91.63% -68.74%
Earnings before Tax (EBT) 1 -1,207 912 -1,103 -533 -1,323 -1,130
Net income 1 -1,210 828 -1,111 -534 -1,349 -1,152
Net margin -160.48% 25.82% -98.06% -26.47% -97.33% -70.89%
EPS 2 -125.0 74.51 -90.33 -42.06 -99.06 -68.57
Free Cash Flow 1 -798.5 1,120 -990 -1,451 -364.5 -1,290
FCF margin -105.9% 34.93% -87.38% -71.96% -26.3% -79.36%
FCF Conversion (EBITDA) - 113.5% - - - -
FCF Conversion (Net income) - 135.3% - - - -
Dividend per Share - - - - - -
Announcement Date 3/27/19 3/27/20 3/26/21 3/25/22 3/27/23 3/27/24
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S1 2021 S1 2021 Q3 2022 Q1 2022 S1 2022 Q3 2023 Q1 2023 S1 2023 Q3
Net sales 1 579 430 206 554 839 256 226 500 211
EBITDA - - - - - - - - -
EBIT 1 -375 -777 -392 1 -312 -441 -505 -863 -338
Operating Margin -64.77% -180.7% -190.29% 0.18% -37.19% -172.27% -223.45% -172.6% -160.19%
Earnings before Tax (EBT) 1 -396 -780 -397 -10 -349 -429 -513 -869 -338
Net income 1 -397 -776 -402 -15 -359 -436 -519 -885 -345
Net margin -68.57% -180.47% -195.15% -2.71% -42.79% -170.31% -229.65% -177% -163.51%
EPS 2 -32.60 -62.50 -31.74 -1.120 -26.53 -32.03 -32.78 -53.81 -19.93
Dividend per Share - - - - - - - - -
Announcement Date 8/7/20 8/6/21 11/8/21 5/10/22 8/5/22 11/7/22 5/10/23 8/7/23 11/7/23
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 670 4,188 3,871 3,278 3,080 2,707
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -799 1,120 -990 -1,451 -365 -1,290
ROE (net income / shareholders' equity) -107% 34.9% -28.9% -13.1% -33.9% -30.7%
ROA (Net income/ Total Assets) -36.1% 17.1% -12.9% -6.46% -16.4% -16.2%
Assets 1 3,348 4,840 8,586 8,260 8,241 7,108
Book Value Per Share 2 87.50 331.0 308.0 324.0 256.0 226.0
Cash Flow per Share 2 134.0 422.0 347.0 287.0 238.0 169.0
Capex 1 58 41 64 41 126 11
Capex / Sales 7.69% 1.28% 5.65% 2.03% 9.09% 0.68%
Announcement Date 3/27/19 3/27/20 3/26/21 3/25/22 3/27/23 3/27/24
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CARNA BIOSCIENCES, INC. Stock Carna Biosciences, Inc.
-21.84% 45.48M
MODERNA, INC. Stock Moderna, Inc.
+26.28% 48.09B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.99% 40.43B
LONZA GROUP AG Stock Lonza Group AG
+46.73% 40.62B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.36B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.36% 24.89B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.47% 19.01B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.58% 12.09B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.75% 11.8B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-2.02% 11.88B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 4572 Stock
  4. Financials Carna Biosciences, Inc.